(Updates With closing prices starting in second paragraph.)

Oct. 5 (Bloomberg) -- BioCancell Therapeutics Inc. had its biggest two-day gain in three months after it began a Phase IIB trial for its pancreatic-cancer treatment that was fast-tracked by the U.S. Food and Drug Administration.

The shares rose 4.9 percent to 1.531 shekels at the 4:30 p.m. close in Tel Aviv, taking its two-day advance to 12 percent, the most since July 10.

--Editors: Shanthy Nambiar, Peter Branton

To contact the reporter on this story: Gwen Ackerman in Tel Aviv at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net